Methazolamide

• UNSPSC Description:

  Methazolamide (L584601) is a sulfonamide derivative used as a carbonic anhydrase inhibitor with a Ki of 14 nM for human carbonic anhydrase II. Methazolamide, an intraocular pressure-lowering agent, reduces intraocular pressure elevations associated with glaucoma and other ocular disorders[1][2].

• Target Antigen:

  Carbonic Anhydrase

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Field of Research:

  Inflammation/Immunology; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/methazolamide.html

• Purity:

  99.43

• Solubility:

  DMSO : ≥ 50 mg/mL

• Smiles:

  CC(/N=C1SC(S(=O)(N)=O)=NN/1C)=O

• Molecular Weight:

  236.27

• References & Citations:

  [1]Yang F, et al. HLA-B*59:01: a marker for Stevens-Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese. Pharmacogenomics J. 2016;16(1):83-87.|[2]Abbate F, et al. Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the perfluorobenzoyl analogue of methazolamide. Implications for the drug design of fluorinated inhibitors. J Enzyme Inhib Med Chem. 2003;18(4):303-308.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Clinical Information:

  Launched

• CAS Number:

  554-57-4